Stock Market Reviews

ACOG (Alpha Cognition Inc.) News

Get the latest news, insights, and market updates on ACOG (Alpha Cognition Inc.). Explore the news page 2 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.

• Alpha Cognition Inc. (ACOG) Reports Q3 Loss, Tops Revenue Estimates
  Alpha Cognition Inc. (ACOG) delivered earnings and revenue surprises of +30.23% and +39.61%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
  Nov 13, 2025 - $ACOG
• Alpha Cognition (Nasdaq: ACOG) to Report Third Quarter 2025 Financial Results and Provide Business Update on Thursday, November 13, 2025
  VANCOUVER, British Columbia & DALLAS, October 30, 2025--Alpha Cognition Inc. (Nasdaq: ACOG), a biopharmaceutical company dedicated to advancing treatments for neurodegenerative diseases, today announced that it will report its third quarter 2025 financial results and provide a business update on Thursday, November 13, 2025, at 4:30 p.m. ET, after market close.
  Oct 30, 2025 - $ACOG
• Alpha Cognition, Inc. to Present at Spartan Capital Securities' Second Annual Investor Conference
  Premier Event Showcases Innovative Growth Companies and Connects Them With Leading Institutional Investors NEW YORK, NY - October 15, 2025 (NEWMEDIAWIRE) - Alpha Cognition (NASDAQ: ACOG) today announced that it will present at the Spartan Capital Sec...
  Oct 15, 2025 - $ACOG
• Alpha Cognition to Present Clinical Data at Consultant Pharmacy and Neuroscience Education Institute Meetings
  VANCOUVER, British Columbia & DALLAS, October 14, 2025--Alpha Cognition Inc. (Nasdaq: ACOG) ("Alpha Cognition" or the "Company"), a commercial-stage biopharmaceutical company focused on developing therapies for neurodegenerative diseases, today announced it will present new clinical insights on cholinesterase inhibitors and ZUNVEYL® (Benzgalantamine) at two upcoming scientific meetings: the American Society of Consultant Pharmacists (ASCP) Annual Meeting (October 23–25, 2025) and the Neuroscienc
  Oct 14, 2025 - $ACOG
• Alpha Cognition to Present Clinical Data at ASCP Annual Meeting
  VANCOUVER, British Columbia & DALLAS, October 06, 2025--Alpha Cognition Inc. (Nasdaq: ACOG), a commercial-stage biopharmaceutical company developing therapies for neurodegenerative diseases, today announced it will present new clinical insights on cholinesterase inhibitors and ZUNVEYL® (Benzgalantamine) at the American Society of Consultant Pharmacists (ASCP) Annual Meeting, October 23–25, 2025.
  Oct 6, 2025 - $ACOG
• Alpha Cognition Inc. Announces Pricing of $35 Million Oversubscribed Public Offering of Common Shares
  VANCOUVER, British Columbia & DALLAS, October 01, 2025--Alpha Cognition Inc. (Nasdaq: ACOG) (the "Company"), a commercial-stage biopharmaceutical company dedicated to developing innovative treatments for neurodegenerative diseases, today announced the pricing of its oversubscribed underwritten public offering of 5,600,000 common shares (or pre-funded warrants in lieu thereof), at a public offering price of $6.25 per share. The gross proceeds of the offering are approximately $35.0 million, befor
  Oct 1, 2025 - $ACOG
• Alpha Cognition Inc. Announces Proposed Public Offering of Common Shares
  VANCOUVER, British Columbia & DALLAS, September 30, 2025--Alpha Cognition Inc. (Nasdaq: ACOG) (the "Company"), a commercial-stage biopharmaceutical company dedicated to developing innovative treatments for neurodegenerative diseases, today announced that it is proposing to offer and sell its common shares and, in lieu of common shares to certain investors, pre-funded warrants to purchase its common shares, in an underwritten public offering. In addition, the Company intends to grant the underwri
  Sep 30, 2025 - $ACOG
• Insiders Rewarded With US$150k Addition To Investment As Alpha Cognition Stock Hits US$144m
  Alpha Cognition Inc. ( NASDAQ:ACOG ) insiders who bought shares over the past year were rewarded handsomely last week...
  Sep 9, 2025 - $ACOG
• Alpha Cognition Inc. (Nasdaq: ACOG) Announces Participation in Key September Investor Conferences
  VANCOUVER, British Columbia & DALLAS, August 28, 2025--Alpha Cognition Inc. (Nasdaq: ACOG), a commercial-stage biopharmaceutical company dedicated to developing innovative treatments for neurodegenerative diseases, today announced that Chief Executive Officer Michael McFadden will present at two prominent healthcare investor conferences this September.
  Aug 28, 2025 - $ACOG
• Stonegate Capital Partners Updates Coverage on Alpha Cognition Inc. (ACOG) Q2 2025
  Dallas, Texas--(Newsfile Corp. - August 15, 2025) - Alpha Cognition Inc. (NASDAQ: ACOG): Stonegate Capital Partners updates their coverage on Alpha Cognition Inc. (NASDAQ: ACOG). Alpha Cognition advanced its first full quarter of ZUNVEYL® commercialization in 2Q25, driving meaningful early adoption in the U.S. long-term care (LTC) market and securing a key regulatory milestone in China. By quarter-end, ...
  Aug 15, 2025 - $ACOG